H. Lundbeck AS (CHIX:HLUNBC) FFO


CHIX:HLUNBC H. Lundbeck AS CHIX:HLUNBC
76 GF Score
Price kr41.95
GF Value kr44.68
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is H. Lundbeck AS FFO?

FFO (Funds from operations) only applies to REITs.

CHIX:HLUNBC
76GF Score
H. Lundbeck AS CHIX:HLUNBC
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is H. Lundbeck AS (CHIX:HLUNBC) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of kr41.95 is trading 6.1% below its estimated GF Value™ of kr44.68. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for CHIX:HLUNBC:

  • FFO:
  • GF Value™: kr44.68 vs. price of kr41.95 (6.1% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the CHIX:HLUNBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
76GF Score

Get the complete analysis for CHIX:HLUNBC

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr41.95
Price
kr44.68
GF Value